Literature DB >> 28695468

In vitro antiproliferative study of novel adamantyl pyridin-4-ones.

V Petrović Peroković1, Ž Car2, T Opačak-Bernardi3, I Martin-Kleiner4, M Kralj4, S Tomić2.   

Abstract

The preparation of several N-aryl-substituted (phenyl, p-methylphenyl, p-methoxyphenyl, p-nitrophenyl, p-aminophenyl, p-hydroxyphenyl) 3-hydroxy-2-methylpyridin-4-ones as well as their adamantyl derivatives is described, and their in vitro antitumor properties were investigated. The compounds were synthesized in good yields using efficient synthetic routes and methods. Prepared derivatives were evaluated in an antiproliferative in vitro study on 4 cancer cell lines, namely HCT 116 (colon carcinoma), H 460 (lung carcinoma), MCF-7 (breast carcinoma) and K562 (chronic myelogenous leukemia). All tested compounds showed antiproliferative activity ranging from moderate to strong on all inspected cell lines with 4 adamantane containing derivatives being active and selective at low micromolar IC[Formula: see text] concentrations on HCT 116, H 460 and MCF-7. LDH cytotoxicity assay revealed that cytotoxic effects occur after 48 h of exposure. It was shown that there was no change in caspase activity in the treated cells, but there were changes in the cell cycle. All treated samples showed reduced number of cells in the S phase with increased G0/G1 (4b, 5a, 5b) and G2/M (4a) phase.

Entities:  

Keywords:  Adamantyl; Antiproliferation; Cancer; Lipophilicity; N-aryl 3-hydroxy-2-methylpyridin-4-ones

Mesh:

Substances:

Year:  2017        PMID: 28695468     DOI: 10.1007/s11030-017-9763-6

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  36 in total

1.  Virtual computational chemistry laboratory--design and description.

Authors:  Igor V Tetko; Johann Gasteiger; Roberto Todeschini; Andrea Mauri; David Livingstone; Peter Ertl; Vladimir A Palyulin; Eugene V Radchenko; Nikolay S Zefirov; Alexander S Makarenko; Vsevolod Yu Tanchuk; Volodymyr V Prokopenko
Journal:  J Comput Aided Mol Des       Date:  2005-06       Impact factor: 3.686

Review 2.  3-Hydroxypyridinone derivatives as metal-sequestering agents for therapeutic use.

Authors:  M Amélia Santos; Sílvia Chaves
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

Review 3.  Novel chelators for cancer treatment: where are we now?

Authors:  Angelica M Merlot; Danuta S Kalinowski; Des R Richardson
Journal:  Antioxid Redox Signal       Date:  2012-05-11       Impact factor: 8.401

4.  Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells.

Authors:  C Kaplinsky; Z Estrov; M H Freedman; E W Gelfand; A Cohen
Journal:  Leukemia       Date:  1987-05       Impact factor: 11.528

5.  Bifunctional 3-hydroxy-4-pyridinone derivatives as potential pharmaceuticals: synthesis, complexation with Fe(III), Al(III) and Ga(III) and in vivo evaluation with 67Ga.

Authors:  M Amélia Santos; Marco Gil; Lurdes Gano; Sílvia Chaves
Journal:  J Biol Inorg Chem       Date:  2005-09-23       Impact factor: 3.358

6.  New lipophilic 3-hydroxy-4-pyridinonate iron(III) complexes: synthesis and EXAFS structural characterisation.

Authors:  Walkiria Schlindwein; Emma Waltham; John Burgess; Norman Binsted; Ana Nunes; Andreia Leite; Maria Rangel
Journal:  Dalton Trans       Date:  2005-11-22       Impact factor: 4.390

7.  Could LogP be a principal determinant of biological activity in 18-crown-6 ethers? Synthesis of biologically active adamantane-substituted diaza-crowns.

Authors:  Fran Supek; Tatjana Šumanovac Ramljak; Marko Marjanović; Maja Buljubašić; Goran Kragol; Nataša Ilić; Tomislav Smuc; Davor Zahradka; Kata Mlinarić-Majerski; Marijeta Kralj
Journal:  Eur J Med Chem       Date:  2011-05-13       Impact factor: 6.514

8.  Synthesis and immunostimulating properties of novel adamant-1-yl tripeptides.

Authors:  Rosana Ribić; Lidija Habjanec; Branka Vranešić; Ruža Frkanec; Srđanka Tomić
Journal:  Chem Biodivers       Date:  2012-04       Impact factor: 2.408

Review 9.  Iron chelators as therapeutic agents for the treatment of cancer.

Authors:  D R Richardson
Journal:  Crit Rev Oncol Hematol       Date:  2002-06       Impact factor: 6.312

10.  Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease.

Authors:  Jeffrey R Liddell; Daniel Obando; Joe Liu; George Ganio; Irene Volitakis; Su San Mok; Peter J Crouch; Anthony R White; Rachel Codd
Journal:  Free Radic Biol Med       Date:  2013-02-04       Impact factor: 7.376

View more
  1 in total

1.  Adamantyl pyran-4-one derivatives and their in vitro antiproliferative activity.

Authors:  Vesna Petrović Peroković; Željka Car; Andrea Usenik; Teuta Opačak-Bernardi; Andrea Jurić; Srđanka Tomić
Journal:  Mol Divers       Date:  2019-04-05       Impact factor: 2.943

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.